This training will provide you with a sense of security in medical practice, which will help you grow personally and professionally”

Cancer patients often present pathologies associated with the oncological process that require care. On the other hand, approaches to cancer patients are often aggressive and can affect other systems, which in the case of frail patients is a major problem in managing risk in therapeutic choices.

The heart is undoubtedly one of the organs most affected by systemic cancer treatments, and considering the importance of its functioning, it becomes an area of study that requires rigor, depth and timeliness.

Cardiological affectation is routinely present in the side effects of most treatments for the oncology patient. The management of the medication, as well as of other therapeutic options, is fundamental in the adjustment of the appropriate dosage for medical praxis. Being up to date on the details of cardiac risk management in this type of patient is a fundamental skill for the physician to possess when dealing with the patient and his or her symptoms.

This program is designed to facilitate the specialist's updating process, so that he/she can include in the clinical practice of their patients all the innovations and the latest knowledge about oncological therapeutics.

Update your knowledge with the postgraduate diploma in Affectation of Cardiac Structure and Function Mediated by Oncologic Treatments"

The postgraduate diploma in Affectation of Cardiac Structure and Function Mediated by Oncologic Treatments contains the most complete and up to date scientific program on the market. The most important features of the program include:

• Development of case studies presented by experts on the cardiotoxic effect of oncological therapies. The graphic, schematic, and eminently practical contents with which they are created provide scientific and practical information on the disciplines that are essential for professional practice
• Developments on the cardiotoxic effect in heart disease
• It contains practical exercises where the self-evaluation process can be carried out to improve learning
• With special emphasis on innovative methodologies in cardiopathies of oncologic toxic etiology
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This postgraduate diploma may be the best investment you can make in the selection of an updating program for two reasons: in addition to updating your knowledge in Affectation of Cardiac Structure and Function Mediated by Oncologic Treatments, you will obtain a postgraduate diploma certificate from TECH - Technological University"

Its teaching staff includes professionals belonging to the field of cardiotoxic cardiopathies, who bring to this training the experience of their work, in addition to recognized specialists belonging to prestigious reference societies and universities.

The multimedia content developed with the latest educational technology will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive training program to train in real situations.

The design of this program is based on Problem-Based Learning, by means of which the student must try to solve the different professional practice situations that arise throughout the course. For this purpose, the student will be assisted by a innovative interactive video system developed by recognized experts in the field of Affectation of Cardiac Structure and Function Mediated by Oncologic Treatments, with extensive teaching experience.

Increase your decision-making confidence by updating your knowledge through this specialist course"

Take the opportunity to learn about the latest advances in the approach to oncologic cardiotoxic heart disease and improve the care of your patients"

The postgraduate diploma in Affectation of Cardiac Structure and Function Mediated by Oncologic Treatments is aimed at facilitating the actions of the physician dedicated to the treatment of oncological pathology, in which it is necessary to accurately interpret the toxic effects of possible occurrence and assess the cardiological risks inherent to the disease process.

This postgraduate diploma is designed for you to update your knowledge in Affectation of Cardiac Structure and Function Mediated by Oncologic Treatments, using the latest educational technology, to contribute with quality and safety to decision making"

General Objective

• Update the knowledge of the specialist Cardiologist, Oncologist and Hematologist in the field of Cardio-Oncology
• Promote work strategies based on a comprehensive approach to the patient as a standard model for achieving excellent care
• Encourage the acquisition of technical skills and abilities, through a powerful audiovisual system, and the possibility of development through online simulation workshops and/or specific training
• To encourage professional stimulation through continuous education and research

Specific Objectives

• Describe the monitoring required by patients during treatment for cardiotoxicity
• Identify biomarkers as a method used to detect cardiotoxicity early, especially troponins and natriuretic peptides
• Deepen the knowledge of echocardiography, with special attention to the "global longitudinal strain" technique as a marker for early detection of cardiac toxicity
• Know the role of cardiac magnetic resonance imaging in the early detection of cardiotoxicity
• Recognize the clinical relevance and mechanisms involved in the onset of ventricular dysfunction and heart failure secondary to cardiac toxicity
• Deepen our knowledge of myocardial involvement caused by anthracyclines
• Identify other chemotherapy drugs with the capacity to produce myocardial toxicity
• Deepen our knowledge of myocardial toxicity induced by monoclonal antibodies, especially tratuzumab
• Recognize the ability of therapies directed against new molecular targets (cellular kinase inhibitors) and proteosome inhibitors to produce ventricular dysfunction and heart failure
• Learn the effects of thoracic radiotherapy on the myocardium
• Improve knowledge in the clinical diagnosis of heart failure associated with cardiotoxicity
• Acquire updated knowledge in the treatment of heart failure and ventricular dysfunction related to oncological treatments
• Know the importance of early detection of myocardial involvement due to cardiotoxicity
• Describe the appropriate action to be taken in the event of an increase in circulating biomarkers during oncologic treatment
• Describe the appropriate response to the appearance of "global longitudinal strain" alteration during oncological treatment
• Learn the monitoring strategy during treatment with anthracyclines
• Learn the monitoring strategy during treatment with monoclonal antibodies, especially trastuzumab
• Learn the monitoring strategy during treatment with cell kinase inhibitors
• Understand the potential causes and mechanisms of ischemic heart disease in the context of cardiac toxicity
• Identify patients at high risk of coronary artery disease
• Define the role of oncological treatments such as fluoropyrimidines in the development of ischemic heart disease
• Acquire updated knowledge on diagnostic methods for coronary artery disease related to cardiotoxic drugs
• Get up to date on the management of acute coronary syndrome in the context of oncologic treatment
• Learn the monitoring strategy in patients who have had coronary ischemia
• Know the clinical relevance of thoracic radiotherapy in the development of coronary artery disease and its mechanisms
• Recognize the risk factors for the development of ischemic heart disease in patients who have received thoracic radiotherapy